Daw Soesoe

Learn More
BACKGROUND Plasmodium falciparum merozoite surface protein 3 is a malaria vaccine candidate that was identified, characterised, and developed based on a unique immuno-clinical approach. The vaccine construct was derived from regions fully conserved among various strains and containing B cell epitopes targeted by human antibodies (from malaria-immune adults)(More)
and CR are affiliated with the Pasteur Institute, which holds a patent on merozoite surface protein 3. analyzed the data. FS organized the clinical trial. AB and CO produced the vaccine. PD wrote the paper. (2005) A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2(11): e344. Copyright: Ó 2005 Druilhe et al.(More)
  • 1